Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

2.

CAR-T cell therapy for cancer causes 'brain fog,' study shows

3.

Squeezing through tiny blood vessels may trigger melanoma cells to spread

4.

Fear of hair loss might cause some to reject cancer treatment

5.

Q&A: Why adolescents and young adults with cancer are falling behind


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot